Search results
Results from the WOW.Com Content Network
Sanofi SA said it would recall popular heartburn medicine Zantac after the medicine was ... Sanofi reported Zantac sales of 127 million euros in 2018 69 million euros over the first half of 2019.
Ranitidine, a heartburn medicine sold under the brand name Zantac among others, was pulled from shelves in 2019, [1] following disclosure [2] of potential carcinogenic effects, [3] [4] which its manufacturers were accused of "engaging in a decades-long scheme to conceal." [5]
In October 2019, the Department of Health and Social Care of the United Kingdom issued a supply distribution alert (SDA/2019/005) for all oral formulations of ranitidine. [106] In October 2019, Sanofi recalled all over-the-counter Zantac in the United States and Canada, [107] [108] [17] Perrigo issued a worldwide recall of ranitidine, [109] [17 ...
In 2019, some manufacturers and pharmacies halted Zantac sales after NDMA was detected in some pills. Shortly afterwards, lawsuits began piling up from people who said they developed cancer after ...
CVS said the move to suspend sales of the over-the-counter heartburn drug was taken out of caution while the FDA continues its review.
In 2019, Dr. Reddy's recalled all ranitidine products in the US market due to contamination with the carcinogen N-nitrosodimethylamine (NDMA). [33] Months later, all brands of ranitidine were recalled and it was taken off the US market, as the carcinogen was an unavoidable byproduct. [34]
For premium support please call: 800-290-4726 more ways to reach us
Ranitidine (Zantac) 2020 Worldwide Found to spontaneously break down into the carcinogen N-nitrosodimethylamine. Rapacuronium (Raplon) 2001 US, multiple markets Withdrawn in many countries because of risk of fatal bronchospasm. [2] Remoxipride: 1993 UK, others Aplastic anemia. [3] rhesus rotavirus vaccine-tetravalent (RotaShield) 1999 US